PDCD1 and lung carcinoma: Dosing and timing remain critical, while butyrate can potentiate PD-1 blockade, systemic SCFAs may dampen CTLA-4 efficacy or NK function in specific contexts, arguing for biomarker-guided, compartment-aware modulation in lung cancer.